Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans

Journal of Rheumatology

Volumn 30, Issue 1, 2003, Pages 60-67

  Oates, Jim C ^a   Levesque, Marc C ^c   Hobbs, Maurine R ^d   Smith, Erica Grace ^h   Molano, Ivan D ^b   Page, Grier P ^e   Hill, Bruce S ^f   Weinberg, J Brice ^c   Cooper, Glinda S ^g   Gilkeson, Gary S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Center for Arthr Rheumatic Diseases   (United States)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^h NONE

Author keywords

Blacks; Genetic predisposition to disease; Microsatellite repeats; Polymorphism (genetics); Promoter regions (genetics)

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MICROSATELLITE DNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETIC REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; NUCLEOTIDE REPEAT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE DISEQUILIBRIUM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICROSATELLITE REPEATS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; SEX DISTRIBUTION; TYROSINE;

EID: 0037229156     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Petri M. The effect of race on incidence and clinical course in systemic lupus erythematosus: The Hopkins Lupus Cohort. J Am Med Wom Assoc 1998;53:9-12.
2. Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4. and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161-72.
3. Tan FK, Arnett FC. The genetics of lupus. Curr Opin Rheumatol 1998;10:399-408.
4. Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". Arthritis Rheum 1998;41:2091-9.
5. Lincoln J, Hoyle CHV, Burnstock G. Nitric oxide in health and disease. New York, NY: Cambridge University Press; 1997.
6. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998;41:1141-51.
7. Wigand R, Meyer J, Busse R, Hecker M. Increased serum N-Ghydroxy-1-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann Rheum Dis 1997;56:330-2.
8. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
9. Rolla G, Brussino L, Bertero MT, et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 1997;24:1066-71.
10. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998;18:41-3.
11. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999;26:318-24.
12. Wanchu A, Khullar M, Sud K, et al. Serum and urine nitrite and citrulline levels among patients with systemic lupus erythematosus: A possible addition to activity parameters? J Clin Rheumatol 2001;7:10-5.
13. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. Proc Assoc Am Physicians 1999;111:611-21.
14. Anstey NM, Weinberg JB, Hassanali MY, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996;184:557-67.
15. Perkins DJ, Kremsner PG, Schmid D, Misukonis MA, Kelly MA, Weinberg JB. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy Gabonese children with prior mild or severe malaria. Infect Immunol 1999;67:4977-81.
16. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998;351:265-6.
17. Burgner D, Xu W, Rockett K, et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998;352:1193-4.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
19. Spitsin SV, Koprowski H, Michaels FH. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter. Mol Med 1996;2:226-35.
20. Levesque MC, Hobbs MR, Anstey NM, et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis 1999;180:1994-2002.
21. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995;364:279-82.
22. Khan J, Brennan DM, Bradley N, Gao BR, Bruckdorfer R, Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998;330:795-801.
23. van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE. Tyrosine modification by reactive nitrogen species: a closer look. Arch Biochem Biophys 1995;319:341-9.
24. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 1994:233:229-40.
25. Sampson JB, Rosen H, Beckman JS. Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. Methods Enzymol 1996;269:210-8.
26. Cooper GS, Parks CG, Treadwell EL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-7.
27. Xie X, Ott J. Testing linkage disequilibrium between a disease gene and marker loci [abstract]. J Hum Genet 1993:53 Suppl:1107A.
28. Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics 1987;117:331-41.
29. Xu WM, Liu LZ, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997;204:165-70.
30. Parra EJ, Marcini A, Akey J, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998;63:1839-51.
31. Parra EJ, Kittles RA, Argyropoulos G, et al. Ancestral proportions and admixture dynamics in geographically defined African-Americans living in South Carolina. Am J Phys Anthropol 2001;114:18-29.
32. Xu W, Humphries S, Tomita M, et al. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease. Nitric Oxide 2000;4:379-83.
33. Kun JF, Mordmuller B, Perkins DJ, et al. Nitric oxide synthase 2 (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis 2001;184:330-6.
34. Warpeha KM, Xu W, Liu L, et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999;13:1825-32.
35. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NF-kappa B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-56.
36. Burgner D, Xu WM, Rockett K, et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998;352:1193-4.
37. Ganster RW, Geller DA. Molecular regulation of inducible nitric oxide synthase. In: Ignarro LJ, editor. Nitric oxide biology and pathobiology. New York: Academic Press; 2000:129-56.
38. de Vera ME, Shapiro RA, Nussler AK, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci USA 1996;93:1054-9.
39. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 2000;13:413-24.
40. Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, et al. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene-Involvement of the RNA-binding protein HuR. J Biol Chem 2000;275:26040-9.
41. Nunokawa Y, Oikawa S, Tanaka S. Expression of human inducible nitric oxide synthase is regulated by both promoter and 3′-regions. Biochem Biophys Res Commun 1997;233:523-6.
42. Kruys V, Kemmer K, Shakhov A, Jongeneel V, Beutler B. Constitutive activity of the tumor necrosis factor promoter is canceled by the 3′-untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect. Proc Natl Acad Sci USA 1992;89:673-7.
43. Gaffney PM, Kearns GM, Shark KB, et al. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sibpair families. Proc Natl Acad Sci USA 1998;95:14875-9.
44. Moser KL, Neas BR, Salmon JE, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Nad Acad Sci USA 1998;95:14869-74.
45. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998;10:690-6.
46. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7.
47. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 1997;40:2207-11.
48. Kleinert H, Boissel JP, Schwarz PM, Forstermann U. Regulation of the expression of nitric oxide synthase isoforms. In: Ignarro LJ, editor. Nitric oxide biology and pathobiology. New York: Academic Press; 2000:105-28.
49. Parks CG, Pandey JP, Dooley MA, et al. Association of systemic lupus erythematosus with genetic polymorphisms in tumor necrosis factor (TNF) alpha and TNF beta: a population-based study [abstract]. Arthritis Rheum 2001;44 Suppl:1182A.